<DOC>
	<DOCNO>NCT02675946</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1 study consist Dose Escalation Phase Dose Expansion Phase evaluate safety , pharmacokinetics , clinical activity .</brief_summary>
	<brief_title>Study CGX1321 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>The purpose Dose Escalation Phase examine safety determine maximum tolerate dose CGX1321 administer subject advance solid tumor include GI tumor relapse refractory consider medically suitable receive standard care treatment meet entry criterion . Once dose identify Dose Escalation Phase , Dose Expansion Phase start . The purpose Dose Expansion Phase continue examine safety confirm final Phase 2 dose CGX1321 administer subject advanced GI tumor meet entry criterion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<criteria>Subjects must meet follow criterion eligible study : Pathologicallyconfirmed , locally advanced metastatic solid tumor relapse refractory consider medically suitable receive standard care treatment ( Dose Escalation Phase ) Histologicallydiagnosed , advance Gl tumor , colorectal adenocarcinoma , gastric adenocarcinoma , pancreatic adenocarcinoma , bile duct carcinoma , hepatocellular carcinoma , esophageal carcinoma relapse refractory consider medically suitable receive standard care treatment ( Dose Expansion Phase ) Eastern Cooperative Oncology Group score 0 2 Minimum life expectancy 3 month Age 18 year old Adequate organ function Recovery prior treatmentrelated toxicity Ability swallow tablet Willingness patient reproductive potential use adequate method contraception 3 month study treatment Prior exposure WNT inhibitor Received previous therapy malignancy within 21 day Major surgery within 4 week first dose study drug Radiotherapy within 2 week first dose study drug Bleeding disorder Bone abnormalities Uncontrolled central nervous system metastasis leptomeningeal metastasis Requirement immunosuppressive agent ( must least 7 day ) Currently receive medication know inhibitor CYP3A4/5 . Subjects currently receive medication know inducer CYP3A4/5 substrates CYP2C8/9 CYP1A2 may exclude . Cardiac abnormality Known human immunodeficiency virus positive , active hepatitis A , B C History additional prior malignancy exception surgically cure carcinomas skin , prostate , bladder , thyroid , cervix carcinoma situ Active systemic infection require intravenous antibiotic within 2 week treatment start GI impairment may compromise absorption study drug Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>WNT inhibitor</keyword>
</DOC>